{"name":"AO GENERIUM","slug":"ao-generium","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"GNR-060","genericName":"GNR-060","slug":"gnr-060","indication":"Type 2 diabetes","status":"phase_3"},{"name":"GNR-069","genericName":"GNR-069","slug":"gnr-069","indication":"Type 2 diabetes","status":"phase_3"},{"name":"GNR-067","genericName":"GNR-067","slug":"gnr-067","indication":"Type 2 diabetes","status":"phase_3"},{"name":"GNR-068","genericName":"GNR-068","slug":"gnr-068","indication":"Type 2 diabetes","status":"phase_3"},{"name":"GNR-086","genericName":"GNR-086","slug":"gnr-086","indication":"Type 2 diabetes","status":"phase_3"},{"name":"Tigerase®","genericName":"Tigerase®","slug":"tigerase","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"Actemra®","genericName":"Actemra®","slug":"actemra","indication":"Other","status":"marketed"},{"name":"Complarate","genericName":"Complarate","slug":"complarate","indication":"Other","status":"phase_3"},{"name":"Metalyse","genericName":"Metalyse","slug":"metalyse","indication":"Acute myocardial infarction","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"infectious","drugs":[{"name":"Genolar® + Symbicort®","genericName":"Genolar® + Symbicort®","slug":"genolar-symbicort","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Xolair® + Symbicort®","genericName":"Xolair® + Symbicort®","slug":"xolair-symbicort","indication":"Asthma maintenance and control","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Tigerase® and best available care","genericName":"Tigerase® and best available care","slug":"tigerase-and-best-available-care","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Elizaria®","genericName":"Elizaria®","slug":"elizaria","indication":"Relapsing forms of multiple sclerosis","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"Ilaris®","genericName":"Ilaris®","slug":"ilaris","indication":"Cryopyrin-associated periodic syndromes (CAPS)","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"rare","drugs":[{"name":"Pulmozyme®","genericName":"Pulmozyme®","slug":"pulmozyme","indication":"Cystic fibrosis to improve pulmonary function and reduce respiratory infections","status":"marketed"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"metabolic","drugs":[{"name":"Revelise (GENERIUM, Russia)","genericName":"Revelise (GENERIUM, Russia)","slug":"revelise-generium-russia","indication":"Anemia associated with chronic kidney disease","status":"phase_3"}]}],"pipeline":[{"name":"GNR-060","genericName":"GNR-060","slug":"gnr-060","phase":"phase_3","mechanism":"GNR-060 is a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"GNR-069","genericName":"GNR-069","slug":"gnr-069","phase":"phase_3","mechanism":"GNR-069 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Tigerase® and best available care","genericName":"Tigerase® and best available care","slug":"tigerase-and-best-available-care","phase":"phase_3","mechanism":"Tigerase works by inhibiting the activity of a specific enzyme.","indications":["Type 2 diabetes","Heart failure"],"catalyst":""},{"name":"Actemra®","genericName":"Actemra®","slug":"actemra","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Complarate","genericName":"Complarate","slug":"complarate","phase":"phase_3","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Elizaria®","genericName":"Elizaria®","slug":"elizaria","phase":"phase_3","mechanism":"Elizaria is a small molecule that targets the S1P1 receptor.","indications":["Relapsing forms of multiple sclerosis"],"catalyst":""},{"name":"GNR-067","genericName":"GNR-067","slug":"gnr-067","phase":"phase_3","mechanism":"GNR-067 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"GNR-068","genericName":"GNR-068","slug":"gnr-068","phase":"phase_3","mechanism":"GNR-068 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"GNR-086","genericName":"GNR-086","slug":"gnr-086","phase":"phase_3","mechanism":"GNR-086 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Genolar® + Symbicort®","genericName":"Genolar® + Symbicort®","slug":"genolar-symbicort","phase":"phase_3","mechanism":"This combination product pairs a long-acting beta-2 agonist (formoterol) with an inhaled corticosteroid (budesonide) to reduce airway inflammation and improve bronchial smooth muscle relaxation in asthma and COPD.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Ilaris®","genericName":"Ilaris®","slug":"ilaris","phase":"marketed","mechanism":"Ilaris (canakinumab) is a monoclonal antibody that blocks interleukin-1 beta (IL-1β), a key inflammatory cytokine, to reduce inflammation and its downstream effects.","indications":["Cryopyrin-associated periodic syndromes (CAPS)","Systemic juvenile idiopathic arthritis (sJIA)","Acute coronary syndrome (ACS) with elevated inflammatory markers","Gout (acute flares and prophylaxis)"],"catalyst":""},{"name":"Metalyse","genericName":"Metalyse","slug":"metalyse","phase":"phase_3","mechanism":"Plasminogen","indications":["Acute myocardial infarction","Ankylosing spondylitis"],"catalyst":""},{"name":"Pulmozyme®","genericName":"Pulmozyme®","slug":"pulmozyme","phase":"marketed","mechanism":"Pulmozyme is a recombinant human DNase that breaks down extracellular DNA in airway secretions to reduce mucus viscosity and improve lung function.","indications":["Cystic fibrosis to improve pulmonary function and reduce respiratory infections"],"catalyst":""},{"name":"Revelise (GENERIUM, Russia)","genericName":"Revelise (GENERIUM, Russia)","slug":"revelise-generium-russia","phase":"phase_3","mechanism":"Revelise is a recombinant human erythropoietin (EPO) analog that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.","indications":["Anemia associated with chronic kidney disease","Chemotherapy-induced anemia"],"catalyst":""},{"name":"Tigerase®","genericName":"Tigerase®","slug":"tigerase","phase":"phase_3","mechanism":"Tigerase is a small molecule that inhibits the activity of a specific enzyme.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Xolair® + Symbicort®","genericName":"Xolair® + Symbicort®","slug":"xolair-symbicort","phase":"phase_3","mechanism":"Xolair (omalizumab) is an anti-IgE antibody that blocks the action of IgE, a protein involved in allergic reactions, while Symbicort (budesonide and formoterol) is a combination of a corticosteroid and a long-acting beta2-adrenergic receptor agonist that reduces inflammation and bronchospasm in the airways.","indications":["Asthma maintenance and control","Chronic idiopathic urticaria"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPY002R1MtZm1GM05nNlM2NE8tLWttcG5oTWxrN1I5LUw4bEQxblBWV013ODNkS3hzLXAtUFJmdmZFRURlVm1IR05vTEI2dlo4VVNuRURmTGU2QXhCNFMySkltRTU3bjFSandIU3p6VDBtdHh5eW5KREdvRDFhLXRBRUJkSFdWM0Z2MHBWbW9OaU5jZ0hsTWdRS0FRNNIBmwFBVV95cUxPY002R1MtZm1GM05nNlM2NE8tLWttcG5oTWxrN1I5LUw4bEQxblBWV013ODNkS3hzLXAtUFJmdmZFRURlVm1IR05vTEI2dlo4VVNuRURmTGU2QXhCNFMySkltRTU3bjFSandIU3p6VDBtdHh5eW5KREdvRDFhLXRBRUJkSFdWM0Z2MHBWbW9OaU5jZ0hsTWdRS0FRNA?oc=5","date":"2023-05-15","type":"pipeline","source":"Новости GxP","summary":"Generium will supply drugs to a number of Middle East countries - Новости GxP","headline":"Generium will supply drugs to a number of Middle East countries - Новости GxP","sentiment":"neutral"}],"patents":[],"drugCount":16,"phaseCounts":{"phase_3":13,"marketed":3},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}